J. Berry

发表

Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation

G. Peoples, G. Clifton, Aaron D. Kirkpatrick, 2016, Journal of Cancer.

Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.

J. Berry, 2005, Clinical therapeutics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma.

M. Raja, J. Berry, B. Khan, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma.

D. Rhydderch, M. Raja, J. Berry, 1997, American journal of clinical oncology.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

E. Mittendorf, A. Philips, G. Peoples, 2018, Clinical immunology.

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

T. Conrads, G. Peoples, K. Darcy, 2016, Oncotarget.

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines

G. Peoples, G. Clifton, J. Berry, 2016, Expert review of clinical immunology.

Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma.

A. El‐Yazigi, A. Ezzat, J. Berry, 1997, Therapeutic drug monitoring.

Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide

J. Berry, D. Matheson, B. Green, 2004, Cancer Immunology, Immunotherapy.

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.

E. Eisenhauer, B. Gyawali, C. Booth, 2021, JAMA oncology.

Impact of pregnancy on non-metastatic breast cancer: a case control study.

A. Jamshed, A. Ezzat, D. Rhydderch, 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial

R. Stuart, S. Bazarbashi, M. Rahal, 2000, Medical oncology.

A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer.

A. El-Warith, S. Bazarbashi, M. Raja, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation.

P. Selby, G. Zulian, B. Houwen, 1989, Bone marrow transplantation.

Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer.

J. Berry, D. Matheson, B. Green, 1987, European journal of cancer & clinical oncology.

The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

E. Mittendorf, G. Peoples, G. Clifton, 2014, Immunotherapy.

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.

T. Wagner, G. Peoples, G. Clifton, 2018, Vaccine.

Abstract OT3-1-09: Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence

N. Ibrahim, G. Peoples, G. Clifton, 2015 .

Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions

G. Peoples, A. Walker, G. Clifton, 2017, Expert review of clinical immunology.

Bone marrow transplantation for Hodgkin's disease.

B. Houwen, J. Berry, J. Russell, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

T. Conrads, G. Peoples, K. Darcy, 2019, Cancer medicine.

Optimization of Oral Etoposide Dosage in Elderly Patients with Non‐Hodgkin's Lymphoma Using the Fraction of Dose Absorbed Measured for Each Patient

A. Ezzat, A. Yusuf, S. Al‐Rawithi, 2000, Journal of clinical pharmacology.

Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats.

C. Vorhees, H. Nau, K. Setchell, 1991, Teratology.

Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.

E. Mittendorf, G. Peoples, S. Perez, 2014 .

Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

J. Murray, E. Mittendorf, G. Peoples, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome in stage III non-Hodgkin's lymphoma in children (UKCCSG study NHL 86)--how much treatment is needed? United Kingdom Children's Cancer Study Group.

C. Pinkerton, M. Gerrard, J. Berry, 1991, British Journal of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients

E. Mittendorf, G. Peoples, G. Clifton, 2013, Journal of Immunotherapy for Cancer.

Abstract B007: Improved disease-free survival in endometrial and ovarian cancer patients with low folate binding protein expression after treatment with the E39 peptide vaccine in a Phase I/IIa trial

G. Peoples, K. Darcy, G. Clifton, 2016 .